Tharimmune to Present Key Findings at Upcoming Conferences

Bridgewater-based Tharimmune, Inc., a company at the forefront of biotechnology focusing on inflammation and immunology therapies, has announced its participation in two significant conferences. At the American College of Gastroenterology Annual Scientific Meeting in Philadelphia, Chief Medical Advisor Nir Barak, M.D., is set to present Phase 1 trial results for TH104, a promising treatment for cholestatic liver disease and associated pruritus. The presentation will occur on October 28, 2024.

Randy Milby, the CEO, will address the 2024 ThinkEquity Conference in New York, sharing insights and engaging with investors. This session will be webcast live on October 30, 2024, with a replay available for 90 days. The participation in these events aims to highlight Tharimmune’s advancements and foster investor interest.